Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
The companies' FIXFc has previously received an EMEA (COMP) orphan medicinal product designation for the treatment of hemophilia B. Pre-clinical studies have shown that this FIXFc compound may have an extended half-life, and a study is currently ongoing to determine the compound's safety and pharmacokinetics in hemophilia B patients.
"This orphan drug designation is very good news for our existing project; Beyond securing market exclusivity for the drug once it is approved, it will allow for certain benefits, including reduced marketing application and license fees, the ability to work with the Office of Orphan Drugs for protocol assistance, and for appropriate meetings with the Division of Blood Applications. This will help us in our efforts to hopefully bring this improved recombinant Factor IXFc hemophilia compound to those patients who have significant unment medical needs." said Martin Nicklasson, CEO of Biovitrum.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.